US pharmaceutical giant AbbVie is going through turbulent times. The company had to announce that its promising schizophrenia drug Emraclidin failed to meet expectations in a crucial Phase 2 study with 752 patients[1]. The stock subsequently plummeted by more than 12 percent, corresponding to a market value loss of approximately $40 billion[1].
This setback is particularly bitter in light of the recent $8.7 billion acquisition of Cerevel Therapeutics, from whose portfolio Emraclidin originated[1]. The development highlights the challenges in the lucrative psychotropic drug market.
The global market for antidepressants was valued at $16.99 billion in 2023 and is expected to grow to over $37 billion by 2036[2]. In parallel, the antipsychotics market, which stood at $16.14 billion in 2023, is also projected to see further growth[3].
For AbbVie, this setback comes at an unfavorable time. The company already recorded a dramatic profit drop of almost 60 percent in 2023, mainly due to the patent expiry of its blockbuster drug Humira[4]. Total revenue fell to $54.3 billion, while net profit plummeted to $4.9 billion[4].
The development of new psychotropic drugs remains a major challenge. An estimated 2.8 million people in the US alone live with schizophrenia[1]. While competitor Bristol Myers Squibb benefits from AbbVie's failure and records stock gains, AbbVie must rethink its strategy[1].
The market for psychiatric drugs is undergoing a transformation. New therapeutic approaches, such as the use of psychedelics in depression treatment, are gaining importance[5]. Australia has become the first country to approve MDMA and psilocybin for therapeutic purposes, while other countries are still hesitant[5].
Despite the setback, AbbVie's Chief Scientific Officer Roopal Thakkar remains confident and announces a thorough analysis of the study results[1]. The future will show whether the company can maintain its position in the highly competitive market for psychotropic drugs.
Sources:
[1] AbbVie plunges: Billion-dollar bet on schizophrenia flops https://www.investmentweek.com/abbvie-sturzt-ab-milliarden-wette-auf-schizophrenie-floppt/
[2] Antidepressant Market Analysis – Global Supply – Research Nester https://www.researchnester.com/de/reports/antidepressants-market/4469
[3] Antipsychotics Market Size, Share | Growth [2024-2032] https://www.fortunebusinessinsights.com/de/industrie-berichte/markt-f-r-antipsychotika-101390
[4] Profit drop not unexpected for AbbVie – Ärzte Zeitung https://www.aerztezeitung.de/Wirtschaft/Gewinneinbruch-kommt-fuer-Abbvie-nicht-unerwartet–446834.html
[5] LSD, Ketamine, Psilocybin, MDMA: Drugs instead of antidepressants https://www.deutschlandfunkkultur.de/psychotherapie-drogen-depressionen-mdma-lsd-pilze-100.html
